This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Euthymics Bioscience, Inc.
Drug Names(s): DOV 21,947, EB-1010
Description: DOV 21,947 is structurally related to DOV 216,303 (DOV 216,303 is a mixture of 2 mirror image compounds, or isomers; DOV 21,947 is one of the isomers). Both are triple-reuptake inhibitors that inhibit the reuptake of the catecholamines serotonin, norepinephrine, and dopamine.
Deal Structure: On August 5, 2004, DOV entered into an agreement with Merck for the worldwide development and commercialization of DOV 21,947 for all therapeutic indications and of DOV 216,303. Merck assumed financial responsibility for development and commercialization of a product containing at least one of the licensed compounds. The parties agreed to work together to clinically develop licensed product and we have reserved the right to co-promote the sales of product in the U.S.
Under the agreement, DOV received a $35.0 million up-front licensing payment. In addition, DOV could receive as much as $300.0 million for achieving certain clinical development and regulatory milestones for multiple territories and approval of two indications, and up to $120.0 million upon achievement of certain sales thresholds. Merck assumed responsibility for the development, manufacturing and commercialization of DOV 21,947 and agreed to pay us royalties on worldwide sales, if any, which increase based upon...See full deal structure in Biomedtracker
Additional information available to subscribers only: